



PREVENTIVE CARE GUIDELINE

Guideline Number: DHMP_PG1005

Effective Date: 12/2009

Guideline Subject: Colorectal Cancer Screening

Revision Date: 12/2010

Pages: 1 of 1

Obsoletes: 10/2004, 10/05, 10/06, 05/07, 12/09


Medical Management Committee Chair

12-15-09
Date

I. PURPOSE:

To define the expected standards of care for Colorectal Cancer Screening.

II. POPULATION:

All eligible DHMP members who are 50 years of age and older in the year in which services are incurred or measured.

III. GOAL:

At least 60% of at risk group (age 50 or older) shall be screened according to one of the criteria.

IV. GUIDELINE:

All enrolled members who are 50 years of age or older shall be offered colorectal cancer screening according to the guidelines laid out in the attached Colorado Clinical Guidelines Collaborative publication on Colorectal Cancer Screening. See also the adapted American Gastroenterology Association Guidelines for Identification and Screening of High Risk Patients. *Note that CT Colonography is not available at Denver Health so this recommendation is only applicable for POS members.

V. REFERENCES:

1. Healthy People 2010 goals for Cancer Screening

VI. ATTACHMENTS:

1. Colorectal Cancer Screening Guidelines, Colorado Clinical Guideline Collaborative, 2009

NOTE:


This guideline is designed to assist providers by providing an analytical framework for the evaluation and treatment of patients, and is not intended either to replace a clinician's judgment or to establish a protocol for all patients with a particular condition.

Colorectal Screening Recommendations

This guideline covers screening of individuals with no signs or symptoms of colorectal cancer. For others, a thorough evaluation is warranted.

Background

- Colorectal cancer (CRC) is the second leading cause of death from cancer in men and women combined.
- Risk is higher among men, in African Americans and some Native Americans, and risk increases with age.
- Screening tests that can detect adenomatous polyps can lead to prevention of colorectal cancer.
- The best choice of a screening test is the one that the health care provider and patient accept and then complete.



^a Individual settings and circumstances influence the choice of a method. Information about all screening options is summarized on page 2 of this guideline, including methods under development.
^b A highly sensitive product such as Hemoccult SENSA or equivalent.
^c Recommended by the Multi-Society Task Force but not the U.S. Preventive Services Task Force (USPSTF). Check with health plan for coverage.
^d Advanced adenomatous polyps are defined as 1 cm or larger, and/or with villous histologic features, and/or with high-grade dysplasia.

Comparison of Screening Methods

This guideline covers screening of individuals with no signs or symptoms of colorectal cancer. For others, a thorough evaluation is warranted.

Preferred Methods	Frequency	Prep Required	Single test Sensitivity for Advanced Neoplasia	USPSTF Evidence Grade ^a	Comments
Colonoscopy	q 10 yrs.	Complete bowel prep	Over 90% sensitive for both cancer and adenomas >1 cm	A	<ul style="list-style-type: none"> Mild sedation is usually used. Risks of perforation and bleeding, mostly associated with polypectomy. Colonoscopy recommended as follow-up for positive findings from any other screening test.
Fecal Occult Blood Testing (FOBT) by high sensitivity guaiac-based tests ^b	q 1 yr.	Diet and medication restrictions	44% to 80% sensitive for cancer but under 70% sensitive for adenomas >1 cm	A	<ul style="list-style-type: none"> A highly sensitive product such as Hemoccult SENSE or equivalent is recommended. 2-3 stool samples from 3 consecutive bowel movements are collected at home. Adherence to annual screening is required for optimal test performance for all FOBT tests. A single sample collected digitally during clinical exam is not adequate for any of the FOBT tests.
Fecal Occult Blood Testing (FOBT) by Fecal Immunochemical Test (FIT) ^b	q 1 yr.	None	61% to 91% sensitive for cancer and 20% to 67% sensitive for adenomas >1 cm	A	<ul style="list-style-type: none"> Fewer demands on patients than the guaiac-based FOBT tests. No dietary or drug restrictions are needed. Stool sampling procedure may be easier. Higher false positive rate than guaiac-based FOBT tests.
Flexible sigmoidoscopy ^b	q 5 yrs.	Complete or partial bowel prep	58% to 70% sensitive for cancer and 50% to 75% sensitive for an adenoma ≥1 cm anywhere in the colorectum	A	<ul style="list-style-type: none"> Combining with FOBT every 1-3 yrs. offers greater protection than sigmoidoscopy alone. Sigmoidoscopy directly visualizes only the distal portion of the colorectum, but increased sensitivity comes from the colonoscopy follow-up of all positive findings. Sedation is not usually used, so some discomfort. Becoming less available.
Methods with insufficient Evidence (USPSTF "I" Grade)					
CT colonography ^b	q 5 yrs.	Complete bowel prep	About 90% sensitive for both cancer and adenomas >1 cm	I	<ul style="list-style-type: none"> Consider for those who cannot tolerate colonoscopy. Check with health plan for coverage. Perforation risk is very low; there is radiation risk; insufflation causes some discomfort. 10-15% of tests result in colonoscopy follow-up. May reveal extra-colonic findings that require further work up in about 10% of patients.
Stool DNA ^b	Unknown	None	Unknown	I	<ul style="list-style-type: none"> Current tests have inconsistent sensitivity.
Methods Not Recommended					
Double Contrast Barium Enema (DCBE) ^b	q 5 yrs.	Complete bowel prep	About 50-75% sensitive for both cancer and adenomas >1 cm	Ungraded	<ul style="list-style-type: none"> Perforation risk is very low, and there is some radiation risk. Evidence base is weak, so not included in the recommended methods by USPSTF. High quality exams are not widely available.
Camera Capsule ^b	Unknown	Complete bowel prep	Unknown	Ungraded	<ul style="list-style-type: none"> An ingestible encapsulated miniature camera captures images of the lining of the colon. This technology is still under development, and is not available in the U.S.
Serologic tests ^b	Unknown	None	Unknown	Ungraded	<ul style="list-style-type: none"> Several types of circulating biomarkers are being studied, including proteins and DNA. These tests are under development, so it is premature to recommend them at this time.

^a Summary of USPSTF evidence grades at: www.coloradoguidelines.org/guidelines/colorectalCancer.asp

^b Colonoscopy recommended for any positive test.

IMPORTANT: Further evaluation is recommended in patients with any signs or symptoms of colorectal cancer, including unexplained iron deficiency anemia not of upper GI origin such as a peptic ulcer; significant changes in bowel pattern; and/or rectal bleeding of undetermined cause, regardless of the presence of hemorrhoids.